These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 3567916)

  • 1. Phase I study of recombinant tumor necrosis factor in cancer patients.
    Blick M; Sherwin SA; Rosenblum M; Gutterman J
    Cancer Res; 1987 Jun; 47(11):2986-9. PubMed ID: 3567916
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Recombinant human tumor necrosis factor-alpha: evidence of an indirect mode of antitumor activity.
    Manda T; Shimomura K; Mukumoto S; Kobayashi K; Mizota T; Hirai O; Matsumoto S; Oku T; Nishigaki F; Mori J
    Cancer Res; 1987 Jul; 47(14):3707-11. PubMed ID: 3594435
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Recombinant human TNF-alpha: preclinical studies and results from early clinical trials.
    Saks S; Rosenblum M
    Immunol Ser; 1992; 56():567-87. PubMed ID: 1550875
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Intravesical RTNF therapy of superficial bladder cancer. A phase I study of recombinant tumor necrosis factor administered intravesically to patients with superficial bladder cancer.
    Grampsas SA; Kahn K; Crawford ED
    Online J Curr Clin Trials; 1994 Mar; Doc No 117():[4845 words; 36 paragraphs]. PubMed ID: 8136939
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase I study of recombinant human tumor necrosis factor-alpha in patients with advanced malignancies.
    Bartsch HH; Nagel GA; Mull R; Flener R; Pfizenmaier K
    Mol Biother; 1988; 1(1):21-9. PubMed ID: 3267369
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase I evaluation of intravenous recombinant human interleukin 12 in patients with advanced malignancies.
    Atkins MB; Robertson MJ; Gordon M; Lotze MT; DeCoste M; DuBois JS; Ritz J; Sandler AB; Edington HD; Garzone PD; Mier JW; Canning CM; Battiato L; Tahara H; Sherman ML
    Clin Cancer Res; 1997 Mar; 3(3):409-17. PubMed ID: 9815699
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Studies on the anti-tumor efficacy of systemically administered recombinant tumor necrosis factor against several murine tumors in vivo.
    Asher A; Mulé JJ; Reichert CM; Shiloni E; Rosenberg SA
    J Immunol; 1987 Feb; 138(3):963-74. PubMed ID: 3805720
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Local treatment of liver metastases with recombinant tumour necrosis factor (rTNF): a phase one study.
    IJzermans JN; van der Schelling GP; Scheringa M; Splinter TA; Marquet RL; Jeekel J
    Neth J Surg; 1991 Aug; 43(4):121-5. PubMed ID: 1944989
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase I/II trial of human recombinant beta-interferon serine in patients with renal cell carcinoma.
    Rinehart J; Malspeis L; Young D; Neidhart J
    Cancer Res; 1986 Oct; 46(10):5364-7. PubMed ID: 3756886
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cytostatic and cytotoxic activity of tumor necrosis factor on human cancer cells.
    Ruggiero V; Latham K; Baglioni C
    J Immunol; 1987 Apr; 138(8):2711-7. PubMed ID: 3031163
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase I study of 24-hour continuous intravenous infusion of recombinant human tumor necrosis factor.
    Steinmetz T; Schaadt M; Gähl R; Schenk V; Diehl V; Pfreundschuh M
    J Biol Response Mod; 1988 Oct; 7(5):417-23. PubMed ID: 3183683
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antitumor effect of systemic administration of novel recombinant tumor necrosis factor (rTNF-S) with less toxicity than conventional rTNF-alpha in vivo.
    Gatanaga T; Noguchi K; Tanabe Y; Inagawa H; Soma G; Mizuno D
    J Biol Response Mod; 1989 Jun; 8(3):278-86. PubMed ID: 2746298
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase I evaluation and pharmacokinetic study of pyrazine-2-diazohydroxide administered as a single bolus intravenous injection in patients with advanced solid tumors.
    Supko JG; Balcerzak SP; Kraut EH
    Cancer Res; 1993 Oct; 53(20):4843-9. PubMed ID: 8402671
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phase I dose-escalation study of tumor necrosis factor-alpha and concomitant radiation therapy.
    Hallahan DE; Vokes EE; Rubin SJ; O'Brien S; Samuels B; Vijaykumar S; Kufe DW; Phillips R; Weichselbaum RR
    Cancer J Sci Am; 1995; 1(3):204-9. PubMed ID: 9166477
    [TBL] [Abstract][Full Text] [Related]  

  • 15. NTP Toxicology and Carcinogenesis Studies of Coumarin (CAS No. 91-64-5) in F344/N Rats and B6C3F1 Mice (Gavage Studies).
    National Toxicology Program
    Natl Toxicol Program Tech Rep Ser; 1993 Sep; 422():1-340. PubMed ID: 12616289
    [TBL] [Abstract][Full Text] [Related]  

  • 16. IL-6/IFN-beta-2 as a circulating hormone. Induction by cytokine administration in humans.
    Jablons DM; Mulé JJ; McIntosh JK; Sehgal PB; May LT; Huang CM; Rosenberg SA; Lotze MT
    J Immunol; 1989 Mar; 142(5):1542-7. PubMed ID: 2783945
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase I evaluation of a synthetic mutant of beta-interferon.
    Hawkins M; Horning S; Konrad M; Anderson S; Sielaff K; Rosno S; Schiesel J; Davis T; DeMets D; Merigan T
    Cancer Res; 1985 Nov; 45(11 Pt 2):5914-20. PubMed ID: 4053062
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase I trial of twice-weekly intravenous interleukin 12 in patients with metastatic renal cell cancer or malignant melanoma: ability to maintain IFN-gamma induction is associated with clinical response.
    Gollob JA; Mier JW; Veenstra K; McDermott DF; Clancy D; Clancy M; Atkins MB
    Clin Cancer Res; 2000 May; 6(5):1678-92. PubMed ID: 10815886
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A safety and pharmacokinetic study of a mixed-backbone oligonucleotide (GEM231) targeting the type I protein kinase A by two-hour infusions in patients with refractory solid tumors.
    Chen HX; Marshall JL; Ness E; Martin RR; Dvorchik B; Rizvi N; Marquis J; McKinlay M; Dahut W; Hawkins MJ
    Clin Cancer Res; 2000 Apr; 6(4):1259-66. PubMed ID: 10778949
    [TBL] [Abstract][Full Text] [Related]  

  • 20. In vivo tumor necrosis factor-alpha as indicator of biologic and clinical response to low-dose SC recombinant interleukin 2.
    Meffert M; Schomburg A; Hänninen EL; Menzel T; Vocke S; Dallmann I; Grosse J; Duensing S; Buer J; Kirchner H
    Anticancer Res; 1995; 15(1):127-32. PubMed ID: 7733621
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.